Picture Kentro Design Corporate and Web Design Berlin 600x60px
Person › Details

Michel Vounatsos (Biogen Inc. (Nasdaq: BIIB))

Vounatsos, Michel (Biogen 201604– Chief Commercial Officer before 20y at Merck)


Organisations Organisation Biogen Inc. (Nasdaq: BIIB)
  Group Biogen (Group)
  Former/major organisation Merck (US) (MSD) (Group)
Products Product biopharmaceutical
  Product 2 Avonex®

Biogen Inc.. (3/30/16). "Press Release: Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer". Cambridge, MA.

Will Provide Operational and Strategic Leadership to Biogen’s Global Commercial Enterprise

Biogen (NASDAQ: BIIB) today announced the appointment of Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016.

Mr. Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the continued growth of Biogen’s product portfolio and the development of the commercial infrastructure and approach to support the company’s key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team.

“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” said Dr. Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organization to support our increasingly robust and diverse pipeline.”

Mr. Vounatsos comes to Biogen after a 20 year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.

“I am excited to work with my new colleagues to deliver on the unique promise of the Biogen pipeline as we seek to transform the lives of patients with neurodegenerative and rare diseases around the world,” said Mr. Vounatsos. “As I move to Biogen, I am grateful to the team at Merck for the tremendous opportunities I have had over the past two decades.”

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit Follow us on Twitter.


Media Contact:
Todd Cooper, +1-781-464-3260
Investor Contact:
Benjamin Strain, +1-781-464-2442

Record changed: 2019-03-12


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Michel Vounatsos

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top